Trial reportEuropean journal of clinical pharmacology2012
Pharmacokinetics of buccal and intranasal lorazepam in healthy adult volunteers.
Trial report in European journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 28 citations in OpenAlex.
- Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial.Epilepsia · 2021Trial
- Translational Considerations in the Development of Intranasal Treatments for Epilepsy.Pharmaceutics · 2023Review
- Effect of administration method, animal weight and age on the intranasal delivery of drugs to the brain.Journal of neuroscience methods · 2017Article
- Alleviation of Oxidative Damage and Involvement of Nrf2-ARE Pathway in Mesodopaminergic System and Hippocampus of Status Epilepticus Rats Pretreated by Intranasal Pentoxifylline.Oxidative medicine and cellular longevity · 2017Article
- The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders.Molecular psychiatry · 2016Review
- Pharmacotherapy for Status Epilepticus.Drugs · 2015Review
- Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability.Patient preference and adherence · 2013Article
- Buccal and intranasal lorazepam clinical pharmacokinetics: can it adequately compete with intravenous lorazepam in pediatric care patients?European journal of clinical pharmacology · 2012Article
- Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGReview
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the plasma-concentration profile of lorazepam when administered by the intranasal and buccal routes to determine their utility for the treatment of prolonged seizures.
methodsOn two occasions separated by at least 7 days washout, 12 healthy adult male volunteers received 2 mg of lorazepam via the intranasal or buccal route. Blood samples were collected at time periods from 0 to 48 h, and pharmacokinetic parameters were determined.
resultsLorazepam was well absorbed from both administration routes; however, there was a more pronounced lag phase with the buccal route and absorption was more rapid from the intranasal route.
conclusionsIntranasal lorazepam has more favourable pharmacokinetics than buccal lorazepam when considering the need for the rapid blood concentrations required for seizure termination. Further clinical evaluation of this route is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.